BioWorld

May 4, 2005

View Archived Issues

Kos Enters Cardio Area, Gets Biovail Products For $104M

Getting a stronger foothold in the cardiovascular therapeutic area, Kos Pharmaceuticals Inc. paid $104 million in cash to Biovail Corp. for U.S. sales and marketing rights to Cardizem LA. (BioWorld Today) Read More

InKine Files NDA For Bowel Cleansing Product INKP-102

Read More

Combo-Chemo Approach Nets $40M In VC Money For Celator

Read More

Genmab Licenses HuMax-TAC To Serono In Deal Worth Up To $40M

Read More

BioShield II Introduced By Bipartisan Group In Senate

Read More

Correction

Read More

Other News To Note

Read More